Efficient drug discovery pipeline and lead compounds for Alzheimer's disease

Applications: Multi-target directed ligands (MTDL) drug development pipeline for Alzheimer’s Disease (AD).

High-throughput platform for testing newly synthesized compounds for Alzheimer’s Disease.

Faster approach to drug development.

This technology is a computational platform that integrates Mendelian randomization with AlphaFold3 to identify the causal protein biomarkers in Alzheimer’s Disease and guide drug target discovery.

Diagnostic assays for Alzheimer’s and other neurodegenerative diseases.

This gap makes it incredibly challenging to prioritize biologically relevant targets in drug development.

These zebrafish lines have been validated in vivo and compared to human Alzheimer’s disease cohort datasets.

This technology is a set of transgenic zebrafish lines expressing hallmark proteins of Alzheimer’s disease with similar pathology to human brains for use as a tool in early drug development.

Unmet Need: Accurate in vivo model for Alzheimer’s disease that mimics human pathologies.